John Crispino

21 hours ago | curetoday.com | John Crispino

In his research into myeloproliferative neoplasms, or MPNs, John Crispino is focused on a couple of key areas when it comes to understanding the underlying biology of the disease, as he explained in an interview with CURE. Crispino is the director of the division of experimental hematology at St. Jude Children’s Research Hospital in Memphis, Tennessee, where he is also the Wall Street Committee Endowed Chair and principal investigator of the Crispino Lab.

2 weeks ago | onlinelibrary.wiley.com | John Crispino

Use the link below to share a full-text version of this article with your friends and colleagues. Learn more. I have read and accept the Wiley Online Library Terms and Conditions of UseI have read and accept the Wiley Online Library Terms and Conditions of UseJ.D.C. is an advisor to Alethiomics and receives research funding from Syndax. The other author declares no conflicts of interest. No abstract is available for this article.

Dec 19, 2023 | nature.com | John Crispino

Correction to: Leukemia https://doi.org/10.1038/s41375-023-02096-4, published online 25 November 2023Publisher CorrectionIn this article, the wrong figure and legend appeared as Fig. 1E:Fig. 1 NOTCH1 and USP11 expression levels are positively correlated in T-ALL. A Volcano plot showing Pearson correlation between 52 USPs and NOTCH1 mRNA levels in T-ALL patient samples analyzed from the Pediatric Cancer Genome Project data portal (PeCan, St. Jude, Memphis).

Nov 25, 2023 | nature.com | John Crispino

To the Editor:NOTCH1 is a transmembrane receptor in a highly conserved signaling pathway that controls cell fate decisions in various organisms and tissues. In contrast, its dysregulation is associated with developmental disorders transformation [1]. NOTCH1 is composed of extracellular and intracellular domains.

Mar 15, 2023 | nature.com | John Crispino